Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: lecimibide
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

130804-35-2

130804-35-2 structure

130804-35-2 structure

Name: lecimibide
Chemical Name: 3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfanyl]pentyl]-1-heptylurea
CAS Number: 130804-35-2
Molecular Formula: C₃₄H₄₀F₂N₄OS
Molecular Weight: 590.76900
Catalog: Research Areas Metabolic Disease
Create Date: 2018-08-25 02:54:18
Modify Date: 2024-01-02 17:46:58
Lecimibide (DuP 128) is a potent and specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor for antihyperlipidemia research[1][2].

Name	3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfanyl]pentyl]-1-heptylurea
Synonyms	N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea urea,n'-(2,4-difluorophenyl)-n-[5-[(4,5-diphenyl-1h-imidazol-2-yl)thio]pentyl]-n-heptyl Lecimibide Lecimibide (USAN)

Description	Lecimibide (DuP 128) is a potent and specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor for antihyperlipidemia research[1][2].
Related Catalog	Research Areas >> Metabolic Disease
In Vitro	Lecimibide (DuP 128)(10 μM, 24 h)可以抑制 HepG2 细胞 85% 的细胞酯化反应[1]。
In Vivo	Lecimibide (DuP 128)(i.v., 2.2 mg/kg/day) 在饲养高脂肪和胆固醇的猪中，显著降低了总血浆甘油三酯和极低密度脂蛋白(VLDL)甘油三酯浓度，分别降低了 36% 和 31%。而对总胆固醇、VLDL 胆固醇、LDL 胆固醇、HDL 胆固醇或 LDL apoB 浓度没有显著影响[2]。
References	[1]. L J Wilcox, et al. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res. 2001 May;42(5):725-34. [2]. J R Burnett, et al. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Biochim Biophys Acta. 1998 Jul 31;1393(1):63-79.

Density	1.21g/cm3
Molecular Formula	C₃₄H₄₀F₂N₄OS
Molecular Weight	590.76900
Exact Mass	590.28900
PSA	89.81000
LogP	9.80240
Index of Refraction	1.613

59025-55-7 structure

59025-55-7

136445-76-6 structure

136445-76-6

~58%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

111-68-2 structure

111-68-2

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

542-28-9 structure

542-28-9

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

4509-90-4 structure

4509-90-4

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

130804-27-2 structure

130804-27-2

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

130804-30-7 structure

130804-30-7

2349-58-8 structure

2349-58-8

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

Precursor 7
59025-55-7 136445-76-6 111-68-2 542-28-9
4509-90-4 130804-27-2 2349-58-8
DownStream 0